Computed Properties of Cu2O, Healthcare careers for chemists are once again largely based in laboratories, although increasingly there is opportunity to work at the point of care, helping with patient investigation. Mentioned the application of 1317-39-1, Name is Copper(I) oxide.
Substituted fused heterocyclic compounds of the formula (I) and pharmacologically acceptable salts thereof: STR1wherein R 1 is a group of the formula (II) or (III): STR2R 4 is a substituted phenyl or a pyridyl which may have a substituent. R 5 is hydrogen or the like. R 6 is hydrogen, a C 1-6 alkyl group or the like. D is oxygen or sulfur. E is a CH group or nitrogen. R 2 is hydrogen or the like. R 3 is a 2,4-dioxothiazolidin-5-ylmethyl group or the like. A is a C 1-6 alkylene group. B is oxygen or sulfur. These compounds and salts are useful as the active ingredient of pharmaceutical compositions which can be used to treat patients because these compounds and salts have excellent insulin-resistance improving action, lipid-peroxide-production inhibitory action, 5-lipoxygenase inhibitory action and the like.
The reactant in an enzyme-catalyzed reaction is called a substrate. Enzyme inhibitors cause a decrease in the reaction rate of an enzyme-catalyzed reaction.I hope my blog about 1317-39-1 is helpful to your research.
Reference：
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”